Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Linezolid for Drug-Resistant Tuberculosis

List of authors.
  • Guy Thwaites, F.R.C.P.,
  • and Nhung V. Nguyen, M.D., Ph.D.

The development of a highly effective, oral, 6-month regimen for the treatment of multidrug-resistant tuberculosis, which previously took 18 to 24 months to cure, is one of the defining achievements of the tuberculosis research community in this century. The results of the Nix-TB study, which were published in the Journal in 2020,1 showed that the combination of two new drugs, bedaquiline and pretomanid, with a repurposed oxazolidinone antibiotic agent, linezolid, given for 6 to 9 months to patients with drug-resistant or complicated multidrug-resistant tuberculosis, resulted in a favorable outcome in 98 of 109 patients (90%) at 6 months after the . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Oxford University Clinical Research Unit, Ho Chi Minh City (G.T.), and the National Lung Hospital and the Vietnam National Tuberculosis Program, Hanoi (N.V.N.) — all in Vietnam; and the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.T.).

Print Subscriber? Activate your online access.